表紙
市場調査レポート

AVEO Pharmaceuticals, Inc.:パイプライン製品の分析

AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 204904
出版日 ページ情報 英文 62 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
AVEO Pharmaceuticals, Inc.:パイプライン製品の分析 AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日: 2016年05月31日 ページ情報: 英文 62 Pages
概要

AVEO Pharmaceuticals, Inc.では、各種の抗がん剤の創薬・治験・販売に特化した事業展開を進めています。同社の主要製品には、チボザニブ(Tivozanib、チロシンキナーゼ阻害剤)やFiclatuzumba(肝細胞成長因子の阻害抗体)、AV-203(抗ErbB3モノクローナル抗体)、AV-380(ヒト化IgG1阻害モノクローナル抗体)などがあります。AVEOが独自開発したHuman Response Platformは、新たな種類の治験前がんモデルで、従来型の異種移植片モデルの制約の多くを拡幅できるように設計されています。

当レポートでは、米国のバイオ医薬品企業、AVEO Pharmaceuticals, Inc.(AVEO Oncology)における医薬品の研究開発の進捗状況について分析し、同社の製品パイプラインの構造や、治験の全体的な進捗状況、主要なパイプライン製品のプロファイルと開発状況、同社のプロファイルと最新動向などを調査しております。

目次

AVEO Pharmaceuticals, Inc.:現状

  • 企業概要
  • 主要情報
  • 主要データ

研究開発(R&D)の概況

  • 主な治療領域

パイプライン・レビュー

  • 開発段階別のパイプライン製品
  • パイプライン製品:単剤治療薬
  • パイプライン製品:パートナー製品
    • パートナー製品/併用治療モダリティ
  • パイプライン製品:アウトライセンス製品
    • アウトライセンス製品/併用治療モダリティ

パイプライン製品の概要

  • 後期段階のパイプライン製品
    • 登録が拒否された製品/併用治療モダリティ
  • 治験段階のパイプライン製品
    • 第II相製品/併用治療モダリティ
    • 第I相製品/併用治療モダリティ
  • 初期段階のパイプライン製品
    • 治験前製品/併用治療モダリティ
    • 創薬段階の製品/併用治療モダリティ

薬剤のプロファイル

  • チボザニブ
    • 製品の概要
    • 作用機序
    • 研究開発(R&D)の進展
  • ficlatuzumab
  • AV-203
  • AV-232
  • GP-369
  • Anti-Notch2モノクローナル抗体
  • Anti-Notch3モノクローナル抗体
  • Anti-Notch4モノクローナル抗体
  • AV-380
  • FGFR1阻害モノクローナル抗体
  • FGFR4阻害モノクローナル抗体

パイプラインの分析

  • 標的別
  • 投与方法別
  • 分子の種類別
  • 作用機序別

パイプライン製品の最新動向

開発が休止状態の製品

開発が中止された製品

  • 開発が中止された製品のプロファイル
    • AV-412
    • チボザニブ

企業のステートメント

事業所および子会社

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08059CDB

Summary

Global Markets Direct's, 'AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the AVEO Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AVEO Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of AVEO Pharmaceuticals, Inc.
  • The report provides overview of AVEO Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses AVEO Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features AVEO Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate AVEO Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for AVEO Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding AVEO Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AVEO Pharmaceuticals, Inc. Snapshot
    • AVEO Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • AVEO Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • AVEO Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • AVEO Pharmaceuticals, Inc. - Pipeline Products Glance
    • AVEO Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • AVEO Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • AVEO Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • AVEO Pharmaceuticals, Inc. - Drug Profiles
    • tivozanib hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ficlatuzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-203
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-232
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-353
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GP-369
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-370
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize FGFR1 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize FGFR4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target Notch2 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target Notch3 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target Notch4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AVEO Pharmaceuticals, Inc. - Pipeline Analysis
    • AVEO Pharmaceuticals, Inc. - Pipeline Products by Target
    • AVEO Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • AVEO Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • AVEO Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • AVEO Pharmaceuticals, Inc. - Recent Pipeline Updates
  • AVEO Pharmaceuticals, Inc. - Dormant Projects
  • AVEO Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AV-412
      • tivozanib hydrochloride
  • AVEO Pharmaceuticals, Inc. - Company Statement
  • AVEO Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AVEO Pharmaceuticals, Inc., Key Information
  • AVEO Pharmaceuticals, Inc., Key Facts
  • AVEO Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • AVEO Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • AVEO Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • AVEO Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • AVEO Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016
  • AVEO Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • AVEO Pharmaceuticals, Inc. - Phase III, 2016
  • AVEO Pharmaceuticals, Inc. - Phase II, 2016
  • AVEO Pharmaceuticals, Inc. - Phase I, 2016
  • AVEO Pharmaceuticals, Inc. - Preclinical, 2016
  • AVEO Pharmaceuticals, Inc. - Discovery, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • AVEO Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • AVEO Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • AVEO Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
  • AVEO Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • AVEO Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • AVEO Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • AVEO Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top